“`html
RSV Vaccines Offer Critically important Protection for Older Adults, Major Review Confirms
A comprehensive new analysis supports widespread adoption of respiratory syncytial virus (RSV) vaccination for individuals aged 60 and older, offering a crucial defence against a disease increasingly recognized as a serious threat to senior health.
A large systematic review and meta-analysis, published in JMIR Public Health and Surveillance, examined the efficacy and safety of novel RSV preF protein vaccines. The findings demonstrate a significant reduction in both lower respiratory tract infections (LRTIs) and RSV-associated acute respiratory illnesses (RSV-ARI) among adults 60 years and older.
Rising RSV Burden in an Aging Population
RSV is no longer considered solely a childhood illness. It’s now understood to be a substantial contributor to illness and death in older adults. data from 2019 estimated approximately 5 million acute respiratory tract infections, 500,000 hospitalizations, and 33,000 in-hospital deaths annually among those 60 and older in high-income countries. Projections for 2025 paint a concerning picture, suggesting a rise to 10.9 million cases, 800,000 hospitalizations, and 74,000 deaths, underscoring the urgent need for effective preventative measures.
Robust Evidence from Clinical Trials
Investigators analyzed data from 14 high-quality, randomized, placebo-controlled trials conducted through July 31, 2024. These trials included over 100,000 older adults for efficacy analyses and more than 76,000 participants for safety evaluations. Across five trials involving 101,825 participants, RSV vaccination was linked to a statistically significant decrease in LRTIs compared to the placebo group.
Initial analyses revealed some variability between studies. Though, researchers identified a single outlier study – one that included participants with a higher pre-existing burden of respiratory disease – as the source of this inconsistency. After excluding this study, a revised analysis of four trials, encompassing 99,931 participants, showed a consistent and significant reduction in LRTIs among vaccinated individuals. A similar pattern emerged in the analysis of RSV-ARIs, with vaccination significantly reducing the incidence of these illnesses after excluding the same outlier study.
Safety Profile Confirmed
Safety was assessed across all 14 trials, involving 76,695 participants. While adverse events (AEs), primarily injection site reactions like pain, swelling, and redness, occurred more frequently in the vaccinated group, the analysis found no significant difference in serious AEs between those who received the vaccine and those who received a placebo.
subgroup analyses explored potential sources of variability in AE reporting. Age appeared to play a role, with heterogeneity in AEs related to vaccine components – including adjuvants and formulations containing Ad26.RSV.preF or recombinant RSV preF protein – being more pronounced in younger subgroups, suggesting potential age-related differences in tolerability.
Interestingly, studies with a predominantly White participant population (over 80%) demonstrated significant heterogeneity in overall AEs, while those with 80% or fewer White participants did not. The authors cautioned that this finding could not be definitively attributed to race due to limited subgroup sizes and the influence of other factors, such as vaccine formulation and study design.
